HealthyNCT06096532
Adipose Tissue Blood Flow in Aging Humans
A study testing 75 gm oral glucose load in people with Healthy and Aging, run by Mayo Clinic at 1 site in United States.
Trial summary
The goal of this basic science clinical trial is to understand whether adipose tissue blood flow changes between younger and older healthy adults. The main question[s] it aims to answer are: Is basal and nutrient responsive adipose tissue blood flow (ATBF) different between younger and older adults What molecular and… Read more about this study
- Who is it for?
- Ages 18 to 80 yearsHealthy volunteers can take part
- What is being tested?
- 75 gm oral glucose load
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Feb 2024to 30 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Within the ages of 18-35 years or 65-80 years at time of study visit
- BMI between 20-25.0 kg/m2.
Who cannot join
- Presence of diagnosed cardiometabolic diseases (e.g., Type 2 diabetes, hypertension, Heart Failure)
- Taking prescription anticoagulants
- Taking prescriptions or supplements that effect adipose tissue metabolism (i.e., statins, Thiazolidinediones, niacin, atypical antipsychotics, or fish oil)
- Pregnant or nursing
- Inability to provide written informed consent
- Smokers
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Mayo Clinic Minnesota
Rochester, Minnesota, 55905
Kelli A Lytle, PhD, 507-255-1488, lytle.kelli@mayo.edu
About this study
The goal of this basic science clinical trial is to understand whether adipose tissue blood flow changes between younger and older healthy adults.
The main question[s] it aims to answer are:
- Is basal and nutrient responsive adipose tissue blood flow (ATBF) different between younger and older adults
- What molecular and systemic signatures related to adipose tissue blood flow are altered between these two groups.
Participants will undergo measurements of adipose tissue blood flow using the xenon washout technique, undergo 2 abdominal subcutaneous adipose tissue biopsies, and drink a sugary drink.
Read the detailed description
On Visit 1, volunteers will provide written informed consent (and urine pregnancy test for women of childbearing age), complete a Dual x-ray absorptiometry scan, baseline labs (comprehensive metabolic panel) and a cardiopulmonary exercise test. Participants will arrive fasted at 08:00, and urine pregnancy test for women of childbearing age administered and an intravenous catheter will be placed. Following 30min of supine rest, baseline venous blood samples will be collected. ATBF will be assessed on participants' left abdomen first by measurement of blood flow using 133Xenon washout method. Immediately thereafter, an abdominal adipose tissue biopsy of the left side will be performed but ≥6 cm distant from location of 133Xenon injections. Subjects will them consume 75 gm glucose; because ATBF peaks 30-60 minutes following ingestion of glucose, ATBF measures will start 30 minutes after ingestion on the contralateral side followed immediately by plasma measures and another adipose tissue biopsy. During ATBF measurements, brachial blood pressure will be assessed in two-minute intervals.
- Being tested
- 75 gm oral glucose load
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
75 gm oral glucose loadOther
Consumption of 75 gm oral glucose load in order to test nutrient responsiveness
| Study group | Role | What they receive |
|---|---|---|
| Older Adults | Other | Not described Receives: Other: 75 gm oral glucose load |
| Younger Adults | Active comparator | Not described Receives: Other: 75 gm oral glucose load |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adipose tissue blood flow
blood flow will be measured in the upper body subcutaneous adipose tissue using 133 Xenon washout and reported as blood flow in ml/min/100g adipose tissue.
Measured: Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load
Secondary outcomes (1)
Genomic alterations
RNA-Seq from adipose tissue biopsies
Measured: Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2023
- Study start15 Feb 2024
- Primary completion30 Dec 2028 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS)
- Responsible party
- Principal investigator, Kelli A. Lytle, Mayo Clinic
- Investigators
- Kelli Lytle, PhD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06096532
- Sponsor's protocol ID
- 23-004200
- Other IDs
- UL1TR002377
- Status last verified
- Jan 2026
- First submitted
- 26 Sep 2023
- Last updated
- 1 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Adipose Tissue Blood Flow in Aging Humans
- ClinicalTrials.gov ID
- NCT06096532
- Acronym / sponsor ID
- 23-004200
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Collaborators
- National Center for Advancing Translational Sciences (NCATS)
- Study start
- 15 Feb 2024 (actual)
- Primary completion
- 30 Dec 2028 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 23 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this basic science clinical trial is to understand whether adipose tissue blood flow changes between younger and older healthy adults.
The main question[s] it aims to answer are:
- Is basal and nutrient responsive adipose tissue blood flow (ATBF) different between younger and older adults
- What molecular and systemic signatures related to adipose tissue blood flow are altered between these two groups.
Participants will undergo measurements of adipose tissue blood flow using the xenon washout technique, undergo 2 abdominal subcutaneous adipose tissue biopsies, and drink a sugary drink.
Detailed description
On Visit 1, volunteers will provide written informed consent (and urine pregnancy test for women of childbearing age), complete a Dual x-ray absorptiometry scan, baseline labs (comprehensive metabolic panel) and a cardiopulmonary exercise test. Participants will arrive fasted at 08:00, and urine pregnancy test for women of childbearing age administered and an intravenous catheter will be placed. Following 30min of supine rest, baseline venous blood samples will be collected. ATBF will be assessed on participants' left abdomen first by measurement of blood flow using 133Xenon washout method. Immediately thereafter, an abdominal adipose tissue biopsy of the left side will be performed but ≥6 cm distant from location of 133Xenon injections. Subjects will them consume 75 gm glucose; because ATBF peaks 30-60 minutes following ingestion of glucose, ATBF measures will start 30 minutes after ingestion on the contralateral side followed immediately by plasma measures and another adipose tissue biopsy. During ATBF measurements, brachial blood pressure will be assessed in two-minute intervals.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Older Adults | Other | Other: 75 gm oral glucose load |
| Younger Adults | Active comparator | Other: 75 gm oral glucose load |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Within the ages of 18-35 years or 65-80 years at time of study visit
- BMI between 20-25.0 kg/m2.
Key exclusion criteria (6 listed)
- Presence of diagnosed cardiometabolic diseases (e.g., Type 2 diabetes, hypertension, Heart Failure)
- Taking prescription anticoagulants
- Taking prescriptions or supplements that effect adipose tissue metabolism (i.e., statins, Thiazolidinediones, niacin, atypical antipsychotics, or fish oil)
- Pregnant or nursing
- Inability to provide written informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 75 gm oral glucose loadConsumption of 75 gm oral glucose load in order to test nutrient responsiveness | Other | Older Adults, Younger Adults |
Primary outcome
Adipose tissue blood flow
Time frame: Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load
blood flow will be measured in the upper body subcutaneous adipose tissue using 133 Xenon washout and reported as blood flow in ml/min/100g adipose tissue.
1 secondary outcome
Genomic alterations
Time frame: Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 May 2026.
- Mayo Clinic Clinical TrialsLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Healthy
Not yet recruitingPhase 1
Dynamic Magnetic Resonance Imaging of Human Subarachnoid Space Using Intrathecal Gadolinium Contrast
Healthy Volunteers
RecruitingObservational study
Survey to Determine Incarcerated Persons' Views on Surrogate Decision Making
Healthy Volunteers
Active, not recruitingPhase 1
A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults
Healthy
Not yet recruitingObservational study
Collection and Distribution of Blood Components From Healthy Donors for In Vitro Research Use
Blood Donors, Apheresis
Recruiting
Metabolic Impact of VLCPUFA-Rich Fish Oil: A Clinical Study on Omega-3 Index Enhancement in Healthy Individuals
Fatty Acids, Omega-3, Fish Oils
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kelli Lytle, PhD principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 75 gm oral glucose load in people with Healthy and Aging, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adipose tissue blood flow (time frame: Baseline, pre-intervention fasting and immediately following 75 gm oral glucose load). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 May 2026.